Innovation Pharmaceuticals Inc (IPIX)

[noretreat]

Form 8A12B-uplist announcement number 1



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 8-A



FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934



CELLCEUTIX CORPORATION

(Exact name of registrant as specified in its charter)




Nevada
30-0565645
(State of incorporation or organization) (I.R.S. Employer Identification No.)




100 Cummings Center, Suite 151-B

Beverly, MA 01915

(Address of principal executive offices)



Securities to be registered pursuant to Section 12(b) of the Act:



Title of each class

to be so registered

Name of each exchange on which

each class is to be registered

Common Stock Class A, $0.0001 par value

THE NASDAQ CAPITAL MARKET




If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x



If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ¨



Securities Act registration statement file number to which this form relates: __________ (if applicable)



Securities to be registered pursuant to Section 12(g) of the Act:






--------------------------------------------------------------------------------

(Title of class)








Item 1. Description of Registrant's Securities to be Registered.



The description of the securities of Cellceutix Corporation, a Nevada corporation (the “Company”) set forth in the Company’s Registration Statement on Form S-3 (File No. 333-199725) filed with the Securities and Exchange Commission on October 30, 2014, is incorporated by reference into this Item 1.



Item 2. Exhibits.



Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed hereunder because no other securities of the Company are listed by THE NASDAQ CAPITAL MARKET and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.




2

--------------------------------------------------------------------------------





SIGNATURE



Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.





CELLCEUTIX CORPORATION

Dated: April 25, 2015 By: /s/ Leo Ehrlich
Name: Leo Ehrlich
Title: Chief Executive Officer and Chief Financial Officer




3


--------------------------------------------------------------------------------